Metastatic disease from uveal melanoma: treatment options and future prospects
Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2017-01, Vol.101 (1), p.38-44 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 44 |
|---|---|
| container_issue | 1 |
| container_start_page | 38 |
| container_title | British journal of ophthalmology |
| container_volume | 101 |
| creator | Carvajal, Richard D Schwartz, Gary K Tezel, Tongalp Marr, Brian Francis, Jasmine H Nathan, Paul D |
| description | Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed. This review explores the biology of uveal melanoma and how this relates to ongoing trials of targeted therapies in the metastatic disease setting. In addition, we consider the options to optimise patient management and care. |
| doi_str_mv | 10.1136/bjophthalmol-2016-309034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5256122</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4321420167</sourcerecordid><originalsourceid>FETCH-LOGICAL-b492t-1fb8cbae50d71012ead2938094ccaddf413a9a3394c23b6f38fb2d488f6624bf3</originalsourceid><addsrcrecordid>eNqNkU9v1DAQxS0EotuWr1BZ4sIlrf_FdjggoQraSgUu9GyNE7ubVRwH26nEt69XW6rCidNoxr95mueHEKbknFIuL-wuLtuyhSnEqWGEyoaTjnDxCm2okLqOVPcabQghqqFU0iN0nPOutkxS9RYdMdUqQVW7Qd-_uQK5QBl7PIzZQXbYpxjw-uBgwsFNMMcAH3FJDkpwc8FxKWOcM4Z5wH4ta3J4STEvri_5FL3xMGX37qmeoLuvX35eXje3P65uLj_fNlZ0rDTUW91bcC0ZFCWUORhYxzXpRN_DMHhBOXTAee0Zt9Jz7S0bhNZeSias5yfo00F3WW1wQ1_vSjCZJY0B0m8TYTR_v8zj1tzHB9OyVlLGqsCHJ4EUf60uFxPG3Lup2nVxzYbqlsm2FWSPvv8H3cU1zdVepTRXuiNMVUofqL7-RU7OPx9DidmHZl6GZvahmUNodfXspZnnxT8pVYAfABt2_y_7CNpmqcE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1883789027</pqid></control><display><type>article</type><title>Metastatic disease from uveal melanoma: treatment options and future prospects</title><source>MEDLINE</source><source>PubMed Central</source><creator>Carvajal, Richard D ; Schwartz, Gary K ; Tezel, Tongalp ; Marr, Brian ; Francis, Jasmine H ; Nathan, Paul D</creator><creatorcontrib>Carvajal, Richard D ; Schwartz, Gary K ; Tezel, Tongalp ; Marr, Brian ; Francis, Jasmine H ; Nathan, Paul D</creatorcontrib><description>Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed. This review explores the biology of uveal melanoma and how this relates to ongoing trials of targeted therapies in the metastatic disease setting. In addition, we consider the options to optimise patient management and care.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2016-309034</identifier><identifier>PMID: 27574175</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Humans ; Incidence ; Liver Neoplasms - drug therapy ; Liver Neoplasms - secondary ; Melanoma - drug therapy ; Melanoma - genetics ; Molecular Biology ; Molecular Targeted Therapy - methods ; Neoplasm Metastasis - drug therapy ; Prognosis ; Review ; Uveal Neoplasms - drug therapy ; Uveal Neoplasms - genetics</subject><ispartof>British journal of ophthalmology, 2017-01, Vol.101 (1), p.38-44</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.</rights><rights>Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b492t-1fb8cbae50d71012ead2938094ccaddf413a9a3394c23b6f38fb2d488f6624bf3</citedby><cites>FETCH-LOGICAL-b492t-1fb8cbae50d71012ead2938094ccaddf413a9a3394c23b6f38fb2d488f6624bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256122/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256122/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,723,776,780,788,881,27899,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27574175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carvajal, Richard D</creatorcontrib><creatorcontrib>Schwartz, Gary K</creatorcontrib><creatorcontrib>Tezel, Tongalp</creatorcontrib><creatorcontrib>Marr, Brian</creatorcontrib><creatorcontrib>Francis, Jasmine H</creatorcontrib><creatorcontrib>Nathan, Paul D</creatorcontrib><title>Metastatic disease from uveal melanoma: treatment options and future prospects</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed. This review explores the biology of uveal melanoma and how this relates to ongoing trials of targeted therapies in the metastatic disease setting. In addition, we consider the options to optimise patient management and care.</description><subject>Humans</subject><subject>Incidence</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - secondary</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - genetics</subject><subject>Molecular Biology</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Neoplasm Metastasis - drug therapy</subject><subject>Prognosis</subject><subject>Review</subject><subject>Uveal Neoplasms - drug therapy</subject><subject>Uveal Neoplasms - genetics</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU9v1DAQxS0EotuWr1BZ4sIlrf_FdjggoQraSgUu9GyNE7ubVRwH26nEt69XW6rCidNoxr95mueHEKbknFIuL-wuLtuyhSnEqWGEyoaTjnDxCm2okLqOVPcabQghqqFU0iN0nPOutkxS9RYdMdUqQVW7Qd-_uQK5QBl7PIzZQXbYpxjw-uBgwsFNMMcAH3FJDkpwc8FxKWOcM4Z5wH4ta3J4STEvri_5FL3xMGX37qmeoLuvX35eXje3P65uLj_fNlZ0rDTUW91bcC0ZFCWUORhYxzXpRN_DMHhBOXTAee0Zt9Jz7S0bhNZeSias5yfo00F3WW1wQ1_vSjCZJY0B0m8TYTR_v8zj1tzHB9OyVlLGqsCHJ4EUf60uFxPG3Lup2nVxzYbqlsm2FWSPvv8H3cU1zdVepTRXuiNMVUofqL7-RU7OPx9DidmHZl6GZvahmUNodfXspZnnxT8pVYAfABt2_y_7CNpmqcE</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Carvajal, Richard D</creator><creator>Schwartz, Gary K</creator><creator>Tezel, Tongalp</creator><creator>Marr, Brian</creator><creator>Francis, Jasmine H</creator><creator>Nathan, Paul D</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>Metastatic disease from uveal melanoma: treatment options and future prospects</title><author>Carvajal, Richard D ; Schwartz, Gary K ; Tezel, Tongalp ; Marr, Brian ; Francis, Jasmine H ; Nathan, Paul D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b492t-1fb8cbae50d71012ead2938094ccaddf413a9a3394c23b6f38fb2d488f6624bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Humans</topic><topic>Incidence</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - secondary</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - genetics</topic><topic>Molecular Biology</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Neoplasm Metastasis - drug therapy</topic><topic>Prognosis</topic><topic>Review</topic><topic>Uveal Neoplasms - drug therapy</topic><topic>Uveal Neoplasms - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carvajal, Richard D</creatorcontrib><creatorcontrib>Schwartz, Gary K</creatorcontrib><creatorcontrib>Tezel, Tongalp</creatorcontrib><creatorcontrib>Marr, Brian</creatorcontrib><creatorcontrib>Francis, Jasmine H</creatorcontrib><creatorcontrib>Nathan, Paul D</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carvajal, Richard D</au><au>Schwartz, Gary K</au><au>Tezel, Tongalp</au><au>Marr, Brian</au><au>Francis, Jasmine H</au><au>Nathan, Paul D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metastatic disease from uveal melanoma: treatment options and future prospects</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>101</volume><issue>1</issue><spage>38</spage><epage>44</epage><pages>38-44</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed. This review explores the biology of uveal melanoma and how this relates to ongoing trials of targeted therapies in the metastatic disease setting. In addition, we consider the options to optimise patient management and care.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>27574175</pmid><doi>10.1136/bjophthalmol-2016-309034</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2017-01, Vol.101 (1), p.38-44 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5256122 |
| source | MEDLINE; PubMed Central |
| subjects | Humans Incidence Liver Neoplasms - drug therapy Liver Neoplasms - secondary Melanoma - drug therapy Melanoma - genetics Molecular Biology Molecular Targeted Therapy - methods Neoplasm Metastasis - drug therapy Prognosis Review Uveal Neoplasms - drug therapy Uveal Neoplasms - genetics |
| title | Metastatic disease from uveal melanoma: treatment options and future prospects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A03%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metastatic%20disease%20from%20uveal%20melanoma:%20treatment%20options%20and%20future%20prospects&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Carvajal,%20Richard%20D&rft.date=2017-01-01&rft.volume=101&rft.issue=1&rft.spage=38&rft.epage=44&rft.pages=38-44&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjophthalmol-2016-309034&rft_dat=%3Cproquest_pubme%3E4321420167%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1883789027&rft_id=info:pmid/27574175&rfr_iscdi=true |